|
Low Carbohydrate Products (ALL)
| |
 |
|
A New Natural Patent-Pending
Ingredient for |
STRESS RELATED WEIGHT CONTROL
|
| |
Human Fat/Stress-Related Hormone
Trial Results
37% Cortisol Reduction (P = 0.01)
227% DHEA Increase (P = 0.003) |
Human Open Trial Results
8 out of 10 people felt more relaxed.
7 out of 10 people enjoyed more restful sleep.
9 out of 10 people said it was gentle on the stomach. |
|
Suggested Dosage
250 mg three times daily |
Natural Source
A proprietary blend of patent-pending
extracts
from Magnolia officinalis and Phellodendron amurense |
|
|
Mechanism of
Action
Relora is an exciting new natural stress relief ingredient that
helps control stress-related eating and drinking and has the added
value of being non-sedating. In central nervous system receptor
binding assays, the plant extracts in Relora bind to several
important targets associated with stress. It does not bind to the
benzodiazepine receptors that would cause sedation, yet has relaxing
qualities that have been demonstrated in both an animal model and a
human study. In addition, it normalizes hormone levels associated
with stress-induced weight gain and eating/drinking behavior.
Stress has been shown to play a significant role in a wide variety
of conditions. A large percentage of overweight adults have
excessive abdominal fat due to stress-related over eating. Relora
can maintain healthy levels of cortisol and DHEA in stressed
individuals, induce relaxation, and act as an aid in controlling
weight and stress-related eating or drinking. |
Animal Model
The plant extracts in Relora have been shown to be an effective
non-sedating anti-stress product in an animal model known as the
"Chick Social Separation-Stress Procedure." The excellent results of
the patent-pending extracts in Relora using this model were
published in Psychopharmacology (2001) 153:219-234. |
Safety Studies
An extensive literature review of the chemical constituents along
with the parent plants' use for hundreds of years indicates that
this material is safe for its intended use. An acute toxicity study
in rats (5g/kg) with 14-day observation revealed no untoward effects
of the individual extracts or the combination in Relora except mild
diarrhea and slight sedation in female rats. No side effects are
expected at the recommended human dosage. |
|
Human
Trials
The first formulation of Relora was tested and found to be a safe,
effective, rapid acting, non-sedating dietary supplement that helps
control occasional anxiousness and stress symptoms. Fifty subjects
were treated with Relora for two weeks. The recommended dosage was
200 mg of Relora three times daily. (The new and improved Relora
dosage is 250 mg three times daily.) Based on pre-clinical studies,
Relora was designed and evaluated against the following concepts;
Relora helps control occasional mild anxiousness and stress-related
symptoms, such as: irritability; emotional ups and downs;
restlessness; tense muscles; poor sleep; concentration
difficulties." Post-trial analysis revealed an excellent agreement
(82%) with the pretrial concept. Relaxation was reported by 78% of
the patients. Though the product does not cause significant
sedation, 74% of the patients had a restful sleep. No significant
side effects were reported. When subjects were asked about
drowsiness, only 24% reported that they were drowsy. Relora was
judged to be gentle on the stomach by 94% of the subjects. A second
trial was undertaken to measure cortisol and DHEA levels in patients
with mild to moderate stress. Elevated cortisol levels and depressed
DHEA levels are associated with chronic stress. A two-week regimen
of Relora caused a significant (P = 0.003) increase in salivary DHEA
(227%) and a significant (P = 0.01) decrease in morning salivary
cortisol levels (37%). Cortisol and DHEA levels were returned to
normal in all subjects during the course of Relora. These
significant findings support Relora's ability to relieve stress and
its potential role in weight control and stress-related eating and
drinking behavior. A clinical trial on the final formulation of
Relora is scheduled to begin Fall of 2002. |
|
| *These statements have not been
evaluated by the Food and Drug Administration. This product is not
intended to diagnose, treat, cure, or prevent disease. |
|
|
Click here and
type Relora in the Item name
contains box
|
